VisionPoint Advisory Group’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.19M Sell
3,296
-64
-2% -$21.9K 0.19% 122
2026
Q1
$1.18M Sell
3,360
-462
-12% -$165K 0.22% 106
2025
Q4
$1.25M Buy
3,822
+74
+2% +$23.5K 0.24% 102
2025
Q3
$1.06M Buy
3,748
+247
+7% +$71.6K 0.21% 117
2025
Q2
$978K Sell
3,501
-1,873
-35% -$531K 0.21% 115
2025
Q1
$1.67M Sell
5,374
-184
-3% -$54.3K 0.57% 52
2024
Q4
$1.44M Buy
5,558
+542
+11% +$161K 0.49% 61
2024
Q3
$1.62M Buy
5,016
+881
+21% +$288K 0.55% 54
2024
Q2
$1.29M Buy
4,135
+610
+17% +$179K 0.46% 65
2024
Q1
$1M Buy
3,525
+1,817
+106% +$532K 0.36% 75
2023
Q4
$492K Buy
1,708
+1,049
+159% +$286K 0.18% 94
2023
Q3
$177K Buy
659
+534
+427% +$133K 0.08% 148
2023
Q2
$27.8K Buy
+125
New +$29K 0.01% 258
2021
Q3
Sell
-6,085
Closed -$1.48M 100
2021
Q2
$1.48M Sell
6,085
-2,024
-25% -$498K 0.66% 46
2021
Q1
$2.02M Sell
8,109
-796
-9% -$190K 0.97% 37
2020
Q4
$2.05M Buy
+8,905
New +$2.05M 1.03% 22

Other funds holding AMGN

VisionPoint Advisory Group's AMGN Position: Q2 2026 in Review

VisionPoint Advisory Group reduced its Amgen (AMGN) stake by 1.9% in Q2 2026, selling an estimated $21.9K and leaving 3,296 shares worth $1.19M. The position accounts for 0.19% of the portfolio, ranked #122.

VisionPoint Advisory Group first reported a position in AMGN in Q4 2020 and has held it in 16 quarters since. The position peaked at $2.05M in Q4 2020. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • VisionPoint Advisory Group held 3,296 shares of Amgen worth $1.19M as of Q2 2026.
  • VisionPoint Advisory Group sold 64 Amgen shares in Q2 2026, an estimated $21.9K.
  • Amgen made up 0.19% of VisionPoint Advisory Group's portfolio in Q2 2026, its #122 holding.
  • VisionPoint Advisory Group first reported a position in Amgen in Q4 2020 and has held it in 16 quarters since.
  • VisionPoint Advisory Group's Amgen position peaked at $2.05M in Q4 2020.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on VisionPoint Advisory Group's 13F filing for Q2 2026, filed 7 Jul 2026.